Fatalities after low-dose therapy with methotrexate

被引：0

作者：

Buschmann C. ^{[1
,3
]}

Theile A. ^{[2
]}

Tsokos M. ^{[1
]}

Püschel K. ^{[1
]}

Schulz F. ^{[1
]}

机构：

[1] Institut für Rechtsmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg

[2] Institut für Pathologie, Ruhr-Universität Bochum An Den Berufsgenossenschaftlichen Kliniken Bergmannsheil, Bochum

[3] Institut für Rechtsmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg 22529

来源：

Rechtsmedizin | 2007年 / 17卷 / 2期

关键词：

Chronic inflammatory joint destruction; Complications; Low-dose therapy; Methotrexate;

D O I：

10.1007/s00194-007-0430-6

中图分类号：

学科分类号：

摘要：

A total of four fatal cases from autopsies carried out by the authors are reported where there was a direct causal connection to a low-dose therapy with the folic acid antagonist methotrexate (MTX) at a dosage of 15-25 mg/week. The patients suffered from chronic inflammatory joint destruction of a rheumatic form in addition to other preexisting internal diseases. A low-dose therapy with MTX as the basis is indicated by this form of disease. In all four cases bone marrow damage occurred after MTX treatment which subsequently gave rise to infection and led to the death of the patient. During antirheumatic MTX therapy the indication status must be strictly controlled and close-meshed laboratory controls are necessary during the therapy regime. Furthermore, interaction with other medications must be taken into consideration in order to control the occurrence of other complications such as sepsis or haemorrhagic pneumonia in advance. © 2007 Springer Medizin Verlag.

引用

页码：89 / 94

页数：5

共 13 条

[1]

Guidelines for monitoring drug therapy in rheumatoid arthritis, Arthritis Rheum, 39, pp. 723-731, (1996)

[2]

Berthelot J.M., Maugars Y., Hamidou M., Et al., Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths), Rev Rhum Engl Ed, 62, pp. 477-486, (1995)

[3]

Bruyn G.A., Velthuysen E., Joosten P., Houtman P.M., Pancytopenia related eosinophilia in rheumatoid arthritis: A specific methotrexate phenomenon?, J Rheumatol, 22, pp. 1373-1376, (1995)

[4]

Calvo-Romero J.M., Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis, Ann Pharmacother, 35, pp. 1575-1577, (2001)

[5]

Frenia M., Long K., Methotrexate and nonsteroidal antiinflammatory drug interactions, Ann Pharmacother, 26, pp. 234-237, (1992)

[6]

Kleihues P., Kiessling M., Wiestler O.D., Aguzzi A., Zentrales Nervensystem, Pathologie, (2001)

[7]

Anti-infektiöse Wirkstoffe, Pharmakologie und Toxikologie, (2003)

[8]

Endokrine Drüsen, Pharmakologie und Toxikologie, (2003)

[9]

MacKinnon S.K., Starkebaum G., Wilkens R.F., Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis, Semin Arthritis Rheum, 15, pp. 119-126, (1985)

[10]

Nanke Y., Kotake S., Akama H., Et al., Pancytopenia and colitis with Clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs, Clin Rheumatol, 20, pp. 73-75, (2001)

← 1 2 →